Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy adults , inclusively.
Documented HIV-1 infection (documented by historical data or current validated assay).
Undetectable viral load.
Currently on an ABC-tablet containing regimen for at least 8 weeks.
Willingness to temporarily switch ABC schedule from BID to QD, or vice versa, for 11 days.
Weigh between 40-100kg, inclusive.
You may not be if
Subjects who are receiving tenofovir.
Previous study participation in other experimental drug trial(s) within 30 days before the screening phase of the study.
Subjects who currently regularly take drugs-of-abuse, with the exception of cannabinoids.
Subjects who cannot refrain from taking herbal remedies during the course of the study.
Subjects who regularly consume more than an average amount of alcohol per day.
Poor general health preventing fasting or blood sampling.
Subjects who are not able to discontinue use of hydroxyurea, mycophenolate or ribavirin for 14 days prior to entering the study until discharge from the study.
An unwillingness of a male subject to abstain from sexual intercourse with women of childbearing potential or an unwillingness to use a condom in addition to having their female partner use another form of contraception.
The subject is pregnant or nursing an infant.
History of symptoms consistent with a hypersensitivity reaction to ABC.
Positive HCV Antibody or HepBsAg (Hepatitis B surface antigen).
